AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30703643 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait retraining (all groups)
Number of subjects: 18
Study 30703643 — intervention group
Group type: EXPERIMENTAL
Intervention: FFOOT
Number of subjects: 18
Study 28301035 — intervention group
Group type: EXPERIMENTAL
Intervention: Educative group (EG)
Number of subjects: 775
Study 28301035 — intervention group
Group type: COMPARATOR
Intervention: Comparative group (CG)
Number of subjects: 775
Study 28301035 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral group (BG)
Number of subjects: 775
Study 25451428 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention (PFI) and Treatment As Usual (TAU)
Number of subjects: 137
Study 25451428 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 137
Study 25451428 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention (PFI)
Number of subjects: 137
Study 23553151 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-enriched chocolate (27 g/d; 850 mg flavan-3-ols + 100 mg isoflavones)
Number of subjects: 93
Study 23553151 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-enriched chocolate
Number of subjects: 93
Study 23553151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 22162988 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy A (two standard doses over 28 days)
Number of subjects: 298
Study 22162988 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy B (two double doses over 28 days)
Number of subjects: 298
Study 22162988 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy C (single standard dose of influenza vaccine)
Number of subjects: 298
Study 22162988 — intervention group
Group type: COMPARATOR
Intervention: Strategy D (previous year's standard-dose vaccination)
Number of subjects: 298
Study 18085694 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg/day
Number of subjects: 71
Study 18085694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 18085694 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 71
Study 16282339 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 800 mg twice daily
Number of subjects: 77
Study 16282339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 16282339 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 77
Study 12907205 — intervention group
Group type: EXPERIMENTAL
Intervention: High SES index
Number of subjects: 47800
Study 12907205 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education levels
Number of subjects: 47800
Study 12907205 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher income
Number of subjects: 47800
Study 12907205 — intervention group
Group type: EXPERIMENTAL
Intervention: SES factors (education, occupation, income)
Number of subjects: 47800
Study 10922130 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 1 mg/kg/day for 7 days
Number of subjects: 54
Study 10922130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 8731624 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management plans issued by general practitioners to patients with asthma
Number of subjects: 906
Study 8731624 — intervention group
Group type: COMPARATOR
Intervention: Control group (no self-management plans)
Number of subjects: 906
Study 1329618 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin 400 mg loading dose followed by 200 mg daily for 9 days
Number of subjects: 16
Study 1329618 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin 600 mg loading dose followed by 300 mg daily for 9 days
Number of subjects: 16
Study 1329618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 4019262 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin plus iron supplements
Number of subjects: 81
Study 4019262 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements
Number of subjects: 81
Study 4019262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 31599341 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior radiotherapy (RT)
Number of subjects: 1825
Study 31599341 — intervention group
Group type: EXPERIMENTAL
Intervention: Having breast cancer
Number of subjects: 1825
Study 31599341 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous RT plus having breast cancer
Number of subjects: 1825
Study 30045595 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral fusion (PLF)
Number of subjects: 88
Study 30045595 — intervention group
Group type: COMPARATOR
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 88
Study 27365262 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPP/START criteria intervention
Number of subjects: 732
Study 27365262 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 732
Study 24112670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 619
Study 24112670 — intervention group
Group type: COMPARATOR
Intervention: Control (no ketorolac)
Number of subjects: 619
Study 22487155 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training combined with thigh cuffs pressure of +90 mmHg (CUFF)
Number of subjects: 20
Study 22487155 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 20
Study 22487155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CUFF and CON)
Number of subjects: 20
Study 20660803 — intervention group
Group type: EXPERIMENTAL
Intervention: Autopsy findings in patients classified as sudden death events
Number of subjects: 105
Study 20660803 — intervention group
Group type: EXPERIMENTAL
Intervention: Time after myocardial infarction
Number of subjects: 105
Study 17965424 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg daily
Number of subjects: 4086
Study 17965424 — intervention group
Group type: COMPARATOR
Intervention: diclofenac 75 mg twice daily
Number of subjects: 4086
Study 16195291 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions for prevention (42 trials)
Number of subjects: 77
Study 16195291 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions for treatment (35 trials)
Number of subjects: 77
Study 16195291 — intervention group
Group type: EXPERIMENTAL
Intervention: Funding sources
Number of subjects: 77
Study 16195291 — intervention group
Group type: EXPERIMENTAL
Intervention: Power calculations
Number of subjects: 77
Study 16195291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical considerations
Number of subjects: 77
Study 11849795 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 103
Study 11849795 — intervention group
Group type: COMPARATOR
Intervention: Nonirradiated
Number of subjects: 103
Study 10190667 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic saline infusion
Number of subjects: 164
Study 10190667 — intervention group
Group type: COMPARATOR
Intervention: Extra-amniotic prostaglandin F2alpha
Number of subjects: 164
Study 7674172 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly(methyl methacrylate) intraocular lens
Number of subjects: 59
Study 7674172 — intervention group
Group type: COMPARATOR
Intervention: Heparin-surface-modified lens
Number of subjects: 59
Study 2403065 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg/d)
Number of subjects: 16
Study 2403065 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-appearing placebos with decaffeinated coffee)
Number of subjects: 16
Study 7223262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (3 x 2 g I.V. within 24 hrs, first dose at anesthetic induction)
Number of subjects: 100
Study 7223262 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin-Tobramycin (clindamycin 600 mg - tobramycin 80 mg/8 hrs for 24 hrs, first dose at anesthetic induction)
Number of subjects: 100
Study 31702714 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 79
Study 31702714 — intervention group
Group type: COMPARATOR
Intervention: Phacotrabeculectomy
Number of subjects: 79
Study 31293021 — intervention group
Group type: EXPERIMENTAL
Intervention: N. sativa (2 g/day)
Number of subjects: 50
Study 31293021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28360223 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening (baseline, 1 year, 2 years, 2.5 years)
Number of subjects: 7900
Study 26087864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% ethyl lauroyl arginate (LAE)-containing mouthrinse
Number of subjects: 87
Study 26087864 — intervention group
Group type: COMPARATOR
Intervention: 5% hydroalcohol-negative control
Number of subjects: 87
Study 23955585 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI + FOLFOX4
Number of subjects: 125
Study 23955585 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI‐HD
Number of subjects: 125
Study 23955585 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX7
Number of subjects: 125
Study 23955585 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 125
Study 23955585 — intervention group
Group type: COMPARATOR
Intervention: Control arms (standard chemotherapy)
Number of subjects: 125
Study 23955585 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arms (intensified chemotherapy)
Number of subjects: 125
Study 21565324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 50
Study 21565324 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 19446622 — intervention group
Group type: EXPERIMENTAL
Intervention: PHFST 240 mg single dose
Number of subjects: 116
Study 19446622 — intervention group
Group type: EXPERIMENTAL
Intervention: PHFST 180-210 mg single dose
Number of subjects: 116
Study 19446622 — intervention group
Group type: EXPERIMENTAL
Intervention: PHFST 30-150 mg single dose
Number of subjects: 116
Study 19446622 — intervention group
Group type: EXPERIMENTAL
Intervention: PHFST multiple dosing (60 mg b.i.d. up to 120 mg b.i.d.)
Number of subjects: 116
Study 19446622 — intervention group
Group type: EXPERIMENTAL
Intervention: PHFST
Number of subjects: 116
Study 16519093 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA)
Number of subjects: 29
Study 16519093 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study 11861338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter (PAC) use in low-risk patients undergoing CABG and AAR
Number of subjects: 0
Study 11861338 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10373727 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime mechanical ventilation (DV)
Number of subjects: 34
Study 10373727 — intervention group
Group type: COMPARATOR
Intervention: Nocturnal mechanical ventilation (NV)
Number of subjects: 34
Study 8562752 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of azithromycin orally (single dose)
Number of subjects: 133
Study 8562752 — intervention group
Group type: COMPARATOR
Intervention: 250 mg of ceftriaxone im (single dose)
Number of subjects: 133
Study 8562752 — intervention group
Group type: EXPERIMENTAL
Intervention: Both azithromycin and ceftriaxone
Number of subjects: 133
Study 2248071 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 63
Study 2248071 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 63
Study 6101535 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 76
Study 6101535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 6101535 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo
Number of subjects: 76
Study 6101535 — intervention group
Group type: COMPARATOR
Intervention: Imaginal desensitization
Number of subjects: 76
Study 31583910 — intervention group
Group type: EXPERIMENTAL
Intervention: Right frontal low frequency transcranial magnetic stimulation (TMS)
Number of subjects: 50
Study 31583910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment EEG (quantitative EEG - qEEG)
Number of subjects: 50
Study 30639581 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A injection
Number of subjects: 50
Study 27966572 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Mexican diet
Number of subjects: 53
Study 27966572 — intervention group
Group type: COMPARATOR
Intervention: US diet
Number of subjects: 53
Study 25588169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral digitization (ID)
Number of subjects: 10
Study 25588169 — intervention group
Group type: COMPARATOR
Intervention: Extraoral digitization (ED)
Number of subjects: 10
Study 24161420 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI) - 37.5 Gy in 3.75 Gy per fraction delivered twice daily
Number of subjects: 102
Study 24161420 — intervention group
Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI) - 48 Gy delivered in daily fractions of 2 Gy, with or without additional 10 Gy to the tumor bed
Number of subjects: 102
Study 21371681 — intervention group
Group type: COMPARATOR
Intervention: Naproxcinod 750 mg
Number of subjects: 2734
Study 21371681 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg
Number of subjects: 2734
Study 19265544 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate dialysate (C)
Number of subjects: 25
Study 19265544 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate dialysate with calcium supplementation (C+)
Number of subjects: 25
Study 19265544 — intervention group
Group type: COMPARATOR
Intervention: Acetate dialysate (A)
Number of subjects: 25
Study 17822973 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece AcrySof IOL
Number of subjects: 52
Study 17822973 — intervention group
Group type: COMPARATOR
Intervention: 3-piece AcrySof IOL
Number of subjects: 52
Study 15173725 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamid filter with conventional ultrafiltration
Number of subjects: 41
Study 15173725 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamid filter with modified ultrafiltration
Number of subjects: 41
Study 15173725 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfon filter with conventional ultrafiltration
Number of subjects: 41
Study 15173725 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfon filter with modified ultrafiltration
Number of subjects: 41
Study 15173725 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrafiltration
Number of subjects: 41
Study 15173725 — intervention group
Group type: COMPARATOR
Intervention: Modified ultrafiltration
Number of subjects: 41
Study 11741526 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (specific treatment not mentioned)
Number of subjects: 0
Study 11741526 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimate equation (GEE) technique
Number of subjects: 0
Study 9505912 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab added to intravenous heparin and aspirin regimen
Number of subjects: 2099
Study 9505912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost effectiveness analysis
Number of subjects: 2099
Study 9505912 — intervention group
Group type: EXPERIMENTAL
Intervention: Modelled analysis
Number of subjects: 2099
Study 7977669 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitation services
Number of subjects: 0
Study 2543246 — intervention group
Group type: EXPERIMENTAL
Intervention: Max‐EPA (3.2 g eicosapentaenoic acid and 2.2 g docosahexaenoic acid)
Number of subjects: 17
Study 2543246 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil capsules)
Number of subjects: 17
Study 4969551 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.d.s.
Number of subjects: 16
Study 4969551 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 40 mg t.d.s.
Number of subjects: 16
Study 4969551 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 100 mg t.d.s.
Number of subjects: 16
Study 30789855 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (AO)
Number of subjects: 107
Study 30789855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 107
Study 30020812 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 1gr/day
Number of subjects: 120
Study 30020812 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipidated curcumin 1gr/day
Number of subjects: 120
Study 30020812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28489804 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 46
Study 28489804 — intervention group
Group type: COMPARATOR
Intervention: Aura-i
Number of subjects: 46
Study 28489804 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LMAs
Number of subjects: 46
Study 25605841 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Rituximab (MR)
Number of subjects: 253
Study 25605841 — intervention group
Group type: COMPARATOR
Intervention: Rituximab re-treatment (RR)
Number of subjects: 253
Study 25605841 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MR and RR
Number of subjects: 253
Study 25605841 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidant coping style
Number of subjects: 253
Study 25605841 — intervention group
Group type: EXPERIMENTAL
Intervention: Active coping style
Number of subjects: 253
Study 22921446 — intervention group
Group type: EXPERIMENTAL
Intervention: Envelope flap technique
Number of subjects: 80
Study 22921446 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified triangular flap technique
Number of subjects: 80
Study 21995679 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion (n = 158)
Number of subjects: 316
Study 21995679 — intervention group
Group type: COMPARATOR
Intervention: Conventional moxibustion (n = 158)
Number of subjects: 316
Study 18496812 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic load (LGL) diet (n = 7; 25% energy from protein and 45% from carbohydrates)
Number of subjects: 12
Study 18496812 — intervention group
Group type: COMPARATOR
Intervention: High glycemic load (HGL) diet (n = 5; 15% energy from protein, 55% energy from carbohydrate)
Number of subjects: 12
Study 18496812 — intervention group
Group type: COMPARATOR
Intervention: High glycemic load (HGL) diet
Number of subjects: 12
Study 18496812 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic load (LGL) diet
Number of subjects: 12
Study 15083498 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofar (Julphar, UAE)
Number of subjects: 24
Study 15083498 — intervention group
Group type: COMPARATOR
Intervention: Bristaflam (Bristol Myers Squibb, Egypt)
Number of subjects: 24
Study 11594896 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care model (n = 285)
Number of subjects: 592
Study 11594896 — intervention group
Group type: COMPARATOR
Intervention: Independent care model (n = 307)
Number of subjects: 592
Study 9852408 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcotrans
Number of subjects: 28
Study 9852408 — intervention group
Group type: EXPERIMENTAL
Intervention: Orth‐Evac
Number of subjects: 28
Study 9852408 — intervention group
Group type: EXPERIMENTAL
Intervention: Redon drainage
Number of subjects: 28
Study 9852408 — intervention group
Group type: COMPARATOR
Intervention: Venous blood
Number of subjects: 28
Study 8271292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide 200 mg daily for a median of 32 months
Number of subjects: 65
Study 8271292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fenretinide)
Number of subjects: 65
Study 8271292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 65
Study 2929705 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial tear formulation (solution 15 with demulcent and buffering system, osmolarity 162 mOsm/l)
Number of subjects: 11
Study 2929705 — intervention group
Group type: COMPARATOR
Intervention: Hypotears (control)
Number of subjects: 11
Study 29877679 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Training Periodization (TTP)
Number of subjects: 17
Study 29877679 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Training Periodization (RTP)
Number of subjects: 17
Study 27776763 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of SI14 (upper trapezius muscle)
Number of subjects: 38
Study 27776763 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of SI8 (distant from the UT muscle)
Number of subjects: 38
Study 27776763 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 38
Study 27776763 — intervention group
Group type: COMPARATOR
Intervention: Sham group (R3)
Number of subjects: 38
Study 24849105 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with paclitaxel-eluting first-generation stent
Number of subjects: 1095
Study 24849105 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1095
Study 24849105 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1095
Study 24849105 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1095
Study 22037137 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 12 weeks
Number of subjects: 24
Study 22037137 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 24
Study 20367667 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg/mL hyaluronic acid with pre-incorporated 0.3% lidocaine
Number of subjects: 60
Study 20367667 — intervention group
Group type: COMPARATOR
Intervention: Equivalent product without lidocaine
Number of subjects: 60
Study 18397977 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month thyroid hormone substitution regimen to obtain euthyroidism
Number of subjects: 25
Study 18397977 — intervention group
Group type: COMPARATOR
Intervention: Subclinical hyperthyroidism
Number of subjects: 25
Study 18397977 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study 18397977 — intervention group
Group type: COMPARATOR
Intervention: Patients with hyperthyroidism
Number of subjects: 25
Study 18397977 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hyperthyroidism patients
Number of subjects: 25